Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas

Hirokazu Nagai, Natsumi Takamaru, Go Ohe, Daisuke Uchida, Tetsuya Tamatani, Kenji Fujisawa, Seiji Iwamoto, Youji Miyamoto

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

The purpose of this study was to evaluate the effectiveness and adverse events of combination chemotherapy with oral S-1 administration following docetaxel (DOC) treatment by superselective intra-arterial infusion as neo-adjuvant chemotherapy (NAC) for patients with oral squamous cell carcinoma. Thirteen patients were enrolled in this study (9 men and 4 women, with a mean age of 61.0 years). All patients were given S-1 65 mg/m2 per day for 14 days, and DOC 40-50 mg/m2 by intraarterial infusion was administered. The locoregional response evaluated 3 weeks after administration was 100%, including a 69.2% complete response. According to Oboshi and Shimosato's classification, histological evaluation of surgical specimens revealed that 3 cases were Grade IIa, 4 cases Grade IIb, 1 case Grade IVa, and 4 cases Grade IVc. The severe side effects were neutropenia and cerebral infarction. The present study suggests that combination chemotherapy with S-1 and DOC by superselective intra-arterial infusion would be an effective and safe regimen in NAC for oral squamous cell carcinomas.

Original languageEnglish
Pages (from-to)777-781
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number5
Publication statusPublished - 2011 May 15
Externally publishedYes

Keywords

  • Docetaxel (DOC)
  • Neoadjuvant chemotherapy (NAC)
  • Oral squamous cell carcinoma
  • S-1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas'. Together they form a unique fingerprint.

Cite this